MPO and metabolic dysfunction-associated steatotic liver disease: High MPO associated with impaired kidney function with low (OR 2.2, 95% CI 1.6-3.7) and intermediate (OR 2.0, 95% CI 1.3-3.5) ASCVD risk, and with high FIB-4 or NAFLD scores in low (OR 2.4, 95% CI 1.2-4.7), intermediate (OR 3.1, 95% CI 2.0-6.0), and high (OR 3.8, 95% CI 2.9-7.4) ASCVD risk groups.